Full-Time

CMMS Administrator

Posted on 9/10/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Senior

Marlborough, MA, USA

This position is site-based, requiring full-time presence at Moderna’s site.

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • BS degree in a science/technical field or equivalent combination of education, training and experience.
  • Minimum 5 years of relevant experience working in a cGMP preferred environment.
  • Experience with CMMS required, Blue Mountain and Maximo Regulatory Asset Manager preferred.
  • Excellent technical training skills
  • Strong project management abilities
  • Exceptional communication and collaboration skills
  • Ability to analyze data and generate detailed reports
  • Familiarity with Maximo Mobile design and implementation is a plus
  • This position is site-based, requiring you to be at Moderna’s site full-time. This position is not eligible for remote work.
Responsibilities
  • Ensure efficient and timely processing of work orders within the Maximo system.
  • Conduct regular updates to Assets, Locations, PMs, and Job Plans within the Maximo database.
  • Provide comprehensive classroom-based training to technicians on the use and optimization of the Maximo system.
  • Act as the site representative for the Maximo User Group, ensuring effective communication and collaboration.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

3%

1 year growth

15%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Opening a new vaccine facility in Victoria enhances Moderna's manufacturing capabilities.
  • Strategic investment in China boosts Moderna's presence in the Asian market.
  • Collaboration with Carisma Therapeutics expands mRNA applications to autoimmune diseases.

What critics are saying

  • Potential removal from Nasdaq 100 could impact investor perception and stock liquidity.
  • Reticence in Hong Kong for COVID-19 jab indicates market acceptance challenges.
  • Expansion into China may expose Moderna to geopolitical risks and regulatory challenges.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company has developed one of the earliest and most effective COVID-19 vaccines.
  • Moderna's mRNA platform targets infectious diseases, immuno-oncology, and autoimmune diseases.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE